Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
Braveheart Bio has raised $185.0M in total funding. The most recent round was Series A. The last funding was announced in November 2025.
Braveheart Bio's investors include Andreessen Horowitz, OrbiMed, Forbion Capital Partners, Enavate Sciences, Frazier Life Sciences.
Braveheart Bio is headquartered in San Francisco, United States.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
Braveheart Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Braveheart Bio — Funding & Investors." VCBacked, November 5, 2025, https://www.vcbacked.co/company/braveheart-bio. Accessed October 15, 2026.
VCBacked. (2025). Braveheart Bio — Funding & Investors. Retrieved October 15, 2026, from https://www.vcbacked.co/company/braveheart-bio
{{cite web |title=Braveheart Bio — Funding & Investors |url=https://www.vcbacked.co/company/braveheart-bio |website=VCBacked |access-date=October 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated